In vitro Assessment of Paclitaxel-loaded Niosome Nanoparticles and Their Cytotoxic Effects on the Ovarian Cancer Cell Line A2780CP

Authors

  • Nasrin Khaje Department of Chemistry, Isfahan University of Technology, Isfahan, Iran.
  • Fatemeh Salehan Master of Industrial and Environmental Biotechnology, Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran.
  • Davoud Shakiba School of Medicine, Zhejiang University, Hangzhou, China.
  • Aida Mohammadiun Shabestari School of Medicine, Zhejiang University, Hangzhou, China.
  • Seyedeh Shahed Shoarishoar Gynecologist, Reproductive Health Research Center, Department of Obsterics and Gynecology, Al-Zahra Hospital, School of Medicine, Guilan University of Medicine Sciences, Rasht, Iran.

Keywords:

Nanoniosome, Paclitaxel, ovarian cancer.

Abstract

Background: One of the major concerns in contemporary medical science is the issue of cancer, with ovarian cancer being a significant contributor to cancer-related deaths. A key challenge in treating ovarian cancer is its initial responsiveness followed by resistance to paclitaxel therapy. However, recent advances in nanotechnology, particularly drug delivery systems like niosomes, offer promising solutions.

Methods: Researchers fabricated nanoparticles via the ether injection approach and analyzed them for particle dimensions, surface charge, and medication release characteristics. Subsequently, they employed A2780CP ovarian cancer cell lines to evaluate the impact of nanodrug using an MTT assay.

Results: The average particle size was reported at 190.3 ± 20.6 nm, with a zeta potential of -18.9 ± 2.7 mV. Notably, high encapsulation proficiency (87.6 ± 32%) verified the successfulness of the applied technique. Moreover, the cytotoxicity assessment demonstrated enhanced efficacy of nanodrug over free carboplatin when targeting A2780CP cell lines (P < 0.05).

Conclusion: these findings suggest that pegylated liposomal nanocarriers could be effective carriers for delivering paclitaxel to A2780CP ovarian cancer cell lines.

Downloads

Published

2024-10-05

Issue

Vol. 9 No. 4 (2024)

Section

Research Articles/ Original Work

License

 West Asia Organization for Cabcer Prevention retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License 4 (This permits anyone to copy, distribute, transmit and adapt the published work, provided the original work and source are appropriately cited).